Fig. 1From: 24-month clinical outcomes of a treat-and-extend regimen with ranibizumab for wet age-related macular degeneration in a real life settingClinical outcomes on visual acuity over 24 monthsNote that VA is slightly decreased at 24 months compared to 12-months time point but still significantly better than presentationBack to article page